Dupilumab for COPD with airway inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old and have a doctor's diagnosis of COPD.
- You must be a current or former smoker with at least a 10 pack-year smoking history (for example, smoking one pack a day for 10 years).
- Your COPD should be moderate to severe, meaning your lung function tests show a certain level of breathing limitation.
- You must have had flare-ups (exacerbations) that required treatment or hospitalization, or your COPD symptoms are severe enough to affect daily life.
- You need to be on triple inhaler therapy (or dual therapy if steroids are not right for you) for at least the last 3 months.
- Blood tests must show evidence of Type 2 inflammation, specifically a certain level of eosinophils (a type of white blood cell).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.